JP2012533565A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533565A5
JP2012533565A5 JP2012520810A JP2012520810A JP2012533565A5 JP 2012533565 A5 JP2012533565 A5 JP 2012533565A5 JP 2012520810 A JP2012520810 A JP 2012520810A JP 2012520810 A JP2012520810 A JP 2012520810A JP 2012533565 A5 JP2012533565 A5 JP 2012533565A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
composition according
oral
mgbg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012520810A
Other languages
English (en)
Japanese (ja)
Other versions
JP6112449B2 (ja
JP2012533565A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/042253 external-priority patent/WO2011009039A2/en
Publication of JP2012533565A publication Critical patent/JP2012533565A/ja
Publication of JP2012533565A5 publication Critical patent/JP2012533565A5/ja
Application granted granted Critical
Publication of JP6112449B2 publication Critical patent/JP6112449B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012520810A 2009-07-16 2010-07-16 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法 Active JP6112449B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22606009P 2009-07-16 2009-07-16
US61/226,060 2009-07-16
US29009509P 2009-12-24 2009-12-24
US61/290,095 2009-12-24
PCT/US2010/042253 WO2011009039A2 (en) 2009-07-16 2010-07-16 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015180110A Division JP2016065045A (ja) 2009-07-16 2015-09-11 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法

Publications (3)

Publication Number Publication Date
JP2012533565A JP2012533565A (ja) 2012-12-27
JP2012533565A5 true JP2012533565A5 (enExample) 2013-09-12
JP6112449B2 JP6112449B2 (ja) 2017-04-12

Family

ID=43450234

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012520810A Active JP6112449B2 (ja) 2009-07-16 2010-07-16 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法
JP2015180110A Pending JP2016065045A (ja) 2009-07-16 2015-09-11 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法
JP2018040226A Expired - Fee Related JP6883930B2 (ja) 2009-07-16 2018-03-06 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法
JP2019213582A Pending JP2020063258A (ja) 2009-07-16 2019-11-26 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015180110A Pending JP2016065045A (ja) 2009-07-16 2015-09-11 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法
JP2018040226A Expired - Fee Related JP6883930B2 (ja) 2009-07-16 2018-03-06 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法
JP2019213582A Pending JP2020063258A (ja) 2009-07-16 2019-11-26 Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法

Country Status (11)

Country Link
US (4) US8258186B2 (enExample)
EP (2) EP2453886B1 (enExample)
JP (4) JP6112449B2 (enExample)
CN (2) CN104997762B (enExample)
AU (2) AU2010273277B2 (enExample)
BR (1) BR112012000862A8 (enExample)
CA (1) CA2768018C (enExample)
DK (1) DK2453886T3 (enExample)
ES (1) ES2715173T3 (enExample)
NZ (3) NZ628513A (enExample)
WO (1) WO2011009039A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627676T3 (es) 2007-03-09 2017-07-31 Pathologica Llc MGBG para la regulación de osteopontina y el tratamiento de la esclerosis múltiple
US9675566B2 (en) * 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
NZ628513A (en) 2009-07-16 2016-01-29 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
EP2665471B1 (en) * 2011-01-19 2017-12-27 Pathologica, LLC. Controlled release oral pharmaceutical dosage forms comprising mgbg
WO2013083813A2 (en) * 2011-12-07 2013-06-13 Universität Zürich Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis
US20140107218A1 (en) * 2012-10-15 2014-04-17 Nestec Sa Methods for maintaining eye health and ameliorating opthalmic maladies in animals
WO2014110154A1 (en) * 2013-01-08 2014-07-17 Pathologica Llc Methods and comp0stions for treatment of demyelinating diseases
DK3785706T3 (da) 2016-03-25 2023-09-11 Aminex Therapeutics Inc Biotilgængelige polyaminer
WO2018027149A1 (en) * 2016-08-04 2018-02-08 University Of Miami Methods of treating alport syndrome
JP6840386B2 (ja) * 2017-04-26 2021-03-10 学校法人 関西大学 細胞足場材料製造用組成物ならびに細胞足場材料およびその製造方法
EP4126017A4 (en) * 2020-04-03 2024-05-22 Baylor College of Medicine Tnf-alpha signaling triggers tumor-promoting inflammation that can be targeted to therapy
JP2023545674A (ja) 2020-09-30 2023-10-31 アミネックス セラピューティクス， インコーポレイテッド ポリアミン輸送阻害剤およびｄｆｍｏの配合原薬
WO2024155777A2 (en) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis
WO2024155775A2 (en) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis
WO2024158951A2 (en) * 2023-01-25 2024-08-02 Dare Bioscience, Inc. Compositions and methods for treating dysmenorrhea

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) * 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
US5614557A (en) * 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5580715A (en) 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5698563A (en) 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
EP0946177B1 (en) 1996-09-13 2005-05-04 University Of Florida Research Foundation, Inc. METHOD OF INHIBITING BIOSYNTHESIS OF EIf5A
AR009380A1 (es) 1996-10-21 2000-04-12 Sumitomo Chemical Co Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico
US6083496A (en) 1996-10-22 2000-07-04 Universite Laval Polyamine transport inhibitors
WO1999003823A2 (en) 1997-07-15 1999-01-28 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
US5889061A (en) 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6169115B1 (en) * 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
HK1040993B (en) 1999-04-30 2006-11-10 Cellgate, Inc. Polyamines and their use in therapy
US6544541B1 (en) 1999-06-02 2003-04-08 Cardiovascular Solutions, Inc. Devices and compounds for treating arterial restenosis
WO2002091989A2 (en) 2000-11-08 2002-11-21 Slil Biomedical Corporation Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
US6963010B2 (en) 2001-01-08 2005-11-08 Mediquest Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
US7045550B2 (en) 2001-08-07 2006-05-16 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
CA2454879A1 (en) 2001-08-15 2003-02-27 The Regents Of The University Of California Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
EP1613263A4 (en) 2003-01-31 2007-11-28 Pathologica Llc MONITORING AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20050113455A1 (en) 2003-10-22 2005-05-26 Bergeron Raymond J.Jr. Method and composition for amelioration of pain
AU2004319105A1 (en) 2004-03-29 2005-11-10 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
WO2005107801A2 (en) 2004-04-29 2005-11-17 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies
EP1912635B1 (en) 2005-07-29 2014-03-05 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Use of chk2 kinase inhibitors for cancer treatment
WO2007035957A2 (en) 2005-09-23 2007-03-29 Pathologica, Llc. Methods for treating viral infections using polyamine analogs
WO2007040535A1 (en) 2005-10-03 2007-04-12 Cellgate, Inc. Use of polyamine analogs for treatment and prevention of intestinal polyps
US20080026209A1 (en) * 2006-07-28 2008-01-31 Sunitha Grandhee Automotive panel having polyurethane primer
US20110091418A1 (en) 2006-09-25 2011-04-21 Pathlogica, LLC Methods for treating viral infections using polyamine analogs
ES2627676T3 (es) * 2007-03-09 2017-07-31 Pathologica Llc MGBG para la regulación de osteopontina y el tratamiento de la esclerosis múltiple
WO2008112251A1 (en) 2007-03-14 2008-09-18 Progen Pharmaceuticals, Inc. Cyclopropyl-containing polyamine analogs as disease therapies
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
NZ628513A (en) 2009-07-16 2016-01-29 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2283830A1 (en) 2009-07-23 2011-02-16 Actogenix N.V. Aqueous enteric capsule coating
EP2665471B1 (en) 2011-01-19 2017-12-27 Pathologica, LLC. Controlled release oral pharmaceutical dosage forms comprising mgbg
WO2014110154A1 (en) 2013-01-08 2014-07-17 Pathologica Llc Methods and comp0stions for treatment of demyelinating diseases

Similar Documents

Publication Publication Date Title
JP2012533565A5 (enExample)
CN103096881B (zh) 含有具有不愉快味道的药物的膜制剂
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
JP2014526503A5 (enExample)
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
JP2009102342A5 (enExample)
JP2013511507A5 (enExample)
JP2005507400A5 (enExample)
JP2006506378A5 (enExample)
JP2012255026A5 (enExample)
JP2008535867A5 (enExample)
JP2009536147A5 (enExample)
NZ605469A (en) Nalbuphine-based formulations and uses thereof
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2013541583A5 (enExample)
JP2017506624A5 (enExample)
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
NZ597488A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
JP2014518274A5 (enExample)
JP2012533559A5 (enExample)
JP2012508256A5 (enExample)
JP2016530238A5 (enExample)
JP2012505830A5 (enExample)
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении